DK0990440T3 - Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid - Google Patents

Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid

Info

Publication number
DK0990440T3
DK0990440T3 DK98905636T DK98905636T DK0990440T3 DK 0990440 T3 DK0990440 T3 DK 0990440T3 DK 98905636 T DK98905636 T DK 98905636T DK 98905636 T DK98905636 T DK 98905636T DK 0990440 T3 DK0990440 T3 DK 0990440T3
Authority
DK
Denmark
Prior art keywords
octylphenyl
saccharide
lecithin
diol
propane
Prior art date
Application number
DK98905636T
Other languages
Danish (da)
English (en)
Inventor
Atsushi Sakai
Rumiko Masuda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK0990440T3 publication Critical patent/DK0990440T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98905636T 1997-02-27 1998-02-25 Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid DK0990440T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4366897 1997-02-27
PCT/JP1998/000755 WO1998037875A1 (fr) 1997-02-27 1998-02-25 Composition medicamenteuse

Publications (1)

Publication Number Publication Date
DK0990440T3 true DK0990440T3 (da) 2009-02-23

Family

ID=12670236

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98905636T DK0990440T3 (da) 1997-02-27 1998-02-25 Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid

Country Status (19)

Country Link
US (1) US6277888B1 (ru)
EP (2) EP0990440B1 (ru)
JP (1) JP4153563B2 (ru)
KR (1) KR20000075745A (ru)
CN (1) CN1178653C (ru)
AT (1) ATE412407T1 (ru)
AU (1) AU735406B2 (ru)
BR (1) BR9811453A (ru)
CA (1) CA2282378C (ru)
DE (1) DE69840169D1 (ru)
DK (1) DK0990440T3 (ru)
ES (1) ES2317663T3 (ru)
HK (2) HK1027039A1 (ru)
IL (1) IL131608A (ru)
NZ (1) NZ337823A (ru)
PT (1) PT990440E (ru)
RU (1) RU2188004C2 (ru)
SI (1) SI0990440T1 (ru)
WO (1) WO1998037875A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JP4627356B2 (ja) * 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
KR100836547B1 (ko) * 2002-01-11 2008-06-10 상꾜 가부시키가이샤 아미노 알코올 유도체 또는 포스폰산 유도체 및 이들을함유하는 의약 조성물
EP2316431B1 (en) * 2003-04-08 2015-09-30 Novartis AG Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
WO2005079788A1 (ja) 2004-02-24 2005-09-01 Sankyo Company, Limited アミノアルコール化合物
PL1773307T3 (pl) * 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
WO2006058316A1 (en) * 2004-11-29 2006-06-01 Novartis Ag Dosage regimen of an s1p receptor agonist
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
PT2295049E (pt) * 2005-09-09 2015-03-02 Novartis Ag Tratamento de doenças auto-imunes
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
PT2952177T (pt) 2007-10-12 2021-04-26 Novartis Ag Composições compreendendo moduladores do recetor de fosfato de esfingosina 1 (s1p)
CN101980704A (zh) 2008-03-17 2011-02-23 埃科特莱茵药品有限公司 选择性s1p1受体激动剂的给药方案
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
RU2483749C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде биопленки
RU2483748C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде пластыря
WO2013020069A1 (en) * 2011-08-03 2013-02-07 Ma Zhongmin Treatment of type 2 diabetes with fty720
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612993B2 (ru) 1973-09-03 1981-03-25
US4020159A (en) * 1974-10-08 1977-04-26 Apotheker A. Herbert K.G., Fabrik Pharmazeutischer Praparate Wiesbaden Methods of and medications for treating cardiac disorders by using strophanthin
JPS5562010A (en) * 1978-10-31 1980-05-10 Ajinomoto Co Inc Fat emulsion for intravenous injection
AU5078885A (en) * 1984-12-20 1986-06-26 Warner-Lambert Company Non-irritant detergent
JPS61172814A (ja) * 1985-01-25 1986-08-04 Ss Pharmaceut Co Ltd 安定な低溶血性ビタミンｅ注射液
JPS63152327A (ja) 1987-11-20 1988-06-24 Toyama Chem Co Ltd 脂肪乳剤から成る溶血防止用組成物を含有する製剤
JPH01172814A (ja) 1987-12-26 1989-07-07 Canon Inc レーザーユニット
AU6461090A (en) 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
JPH04173736A (ja) * 1990-11-06 1992-06-22 Nippon Shinyaku Co Ltd 乳化剤
ATE172711T1 (de) 1992-10-21 1998-11-15 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
KR100358922B1 (ko) 1994-08-22 2003-01-24 미쯔비시 웰 파마 가부시키가이샤 벤젠화합물및그의의약으로서의용도
JP3169807B2 (ja) 1995-09-18 2001-05-28 本田技研工業株式会社 ロータ組み付け装置
CA2213989C (en) 1995-12-28 2007-05-29 Yoshitomi Pharmaceutical Industries Ltd. External preparation for topical administration
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
KR100190826B1 (ko) * 1996-08-26 1999-06-01 강재헌 적혈구 용혈 억제용 약제학적 조성물 및 그의제조방법

Also Published As

Publication number Publication date
BR9811453A (pt) 2000-09-12
KR20000075745A (ko) 2000-12-26
AU735406B2 (en) 2001-07-05
EP0990440B1 (en) 2008-10-29
ES2317663T3 (es) 2009-04-16
IL131608A (en) 2003-02-12
SI0990440T1 (sl) 2009-04-30
EP0990440A1 (en) 2000-04-05
EP0990440A4 (en) 2004-04-21
PT990440E (pt) 2009-02-05
HK1027039A1 (en) 2001-01-05
NZ337823A (en) 2001-04-27
ATE412407T1 (de) 2008-11-15
CA2282378C (en) 2008-12-30
HK1027959A1 (en) 2001-02-02
DE69840169D1 (de) 2008-12-11
IL131608A0 (en) 2001-01-28
CA2282378A1 (en) 1998-09-03
US6277888B1 (en) 2001-08-21
CN1253499A (zh) 2000-05-17
CN1178653C (zh) 2004-12-08
RU2188004C2 (ru) 2002-08-27
AU6115598A (en) 1998-09-18
EP2030614A1 (en) 2009-03-04
JP4153563B2 (ja) 2008-09-24
WO1998037875A1 (fr) 1998-09-03

Similar Documents

Publication Publication Date Title
DK0990440T3 (da) Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid
PT1050301E (pt) Composições medicinais contendo 2-amino-2-[2-(4- octilfenil)etil]propano-1,3-diol
IL121625A0 (en) External preparation for topical administration
UY23665A1 (es) Procedimiento para la preparacion de compuesto farmaceutico
BR9507506A (pt) Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico
ATE220542T1 (de) Zweiteilige kapsel zur aufnahme von pharmazeutischen zubereitungen für pulverinhalatoren
RU99123047A (ru) Производное 2-аминопропан-1,3-диола, его фармацевтическое применение и промежуточные продукты для их синтеза
RU99120398A (ru) Фармацевтическая композиция
RU92016244A (ru) Производные сахарина-ингибиторы протеолитических ферментов
ATE316779T1 (de) Implantate zur gesteuerten freisetzung von pharmazeutischen wirkstoffen und verfahren zur herstellung
HUP0202525A2 (hu) Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit
ITRM940571A0 (it) "sale della l-carnitina e composizioni farmaceutiche che lo contengonoper il trattamento di affezioni cutanee"
BR9810452A (pt) Nova combinação de medicamentos contra asma
RU96113317A (ru) Способ постановки ирригационной системы в теноново пространство
KR910009255A (ko) 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체
NO20001895L (no) Anvendelse av glykosaminoglykaner for fremstilling av farmasøytiske preparater for behandling av diabetes assosierte- øyesykdommer
DK0704219T3 (da) Anvendelse af faktor for osteoblastisk celledeling
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
IL110888A (en) Pharmaceutical compositions for the treatment of liver diseases comprising a vasodilating compound
SE9002435D0 (sv) Medel samt foerfarande foer behandling av biologisk implantationsvaevnad
TH25306A (th) วิธีของการใช้สำหรับยับยั้งการสูญเสียกระดูกและการลดคอเลสเทอรอลในซีรัม
TH25306B (th) วิธีของการใช้สำหรับยับยั้งการสูญเสียกระดูกและการลดคอเลสเทอรอลในซีรัม
ITTO971026A1 (it) Estrazione di matrice ossea deantigenata dall'osso animale o umano per uso chirurgico e ortopedico quale sostituto osseo autologo o eterologo per impianti e per uso medico, dermatologico e cosmetico quale carrier di sostanze medicamentose.